IRCT20200105046010N15招募中未知
Pharmacokinetic assessments of Itraconazole capsules in comparison with brand drug SPRANOX
Chemidarou company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 60 years（—）
- 性别
- All
入选标准
- •General health (liver, heart, kidney)
- •Body Mass Index (BMI) between 18-28
- •Informed consent
- •Age between 18-28
- •Both male and female
排除标准
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
已完成
不适用
se of Itraconazole oral solution in Children with Fungal InfectioCTRI/2019/05/019139Dr Ramesh Bhat M30
尚未招募
3 期
Efficacy and safety of itraconazole, SUBA-itraconazole and voriconazole in Recalcitrant Dermatophytosis.CTRI/2024/05/066681I
尚未招募
3 期
A comparative study between oral itraconazole and terbinafine in tinea infectioCTRI/2023/10/058844Mahatma Gandhi Hospital
进行中（未招募）
1 期
Itraconazole as treatment for severe nose bleeding in patients with hereditary hemorrhagic telangiectasiaSevere epistaxis in patients with Hereditary Hemorrhagic Telangiectasia also known as Rendu-Osler-Weber diseaseMedDRA version: 20.0Level: LLTClassification code 10031132Term: Osler-Weber-Rendu diseaseSystem Organ Class: 100000004850MedDRA version: 20.0Level: LLTClassification code 10038554Term: Rendu-Osler-Weber syndromeSystem Organ Class: 100000004850EUCTR2017-003272-31-NLSt. Antonius Ziekenhuis25
已完成
2 期
Efficacy and safety of oral itraconazole in the reduction of epistaxis severity in hereditary hemorrhagic telangiectasiahereditary hemorrhagic telangiectasiaRendu-Osler-Weber disease100075101004704310047075NL-OMON46365Sint Antonius Ziekenhuis25